Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia
暂无分享,去创建一个
C. Boshoff | D. Cornforth | A. Copas | D. Bourboulia | I. Williams | D. Aldam | E. Allen | D. Lagos
[1] A. Jemal,et al. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. , 2002, Journal of the National Cancer Institute.
[2] B. Gazzard,et al. Prospective Study of the Effects of Antiretroviral Therapy on Kaposi Sarcoma‐Associated Herpesvirus Infection in Patients With and Without Kaposi Sarcoma , 2002, Journal of acquired immune deficiency syndromes.
[3] E. Cesarman,et al. Spectrum of Kaposi's Sarcoma-Associated Herpesvirus, or Human Herpesvirus 8, Diseases , 2002, Clinical Microbiology Reviews.
[4] T. Sturgeon,et al. Epstein‐Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV‐infected patients treated with HAART , 2002, Journal of medical virology.
[5] R. Gavioli,et al. Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8 , 2002, Immunology.
[6] Jaap M Middeldorp,et al. High Epstein–Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology , 2002, AIDS.
[7] C. Rinaldo,et al. Identification of an HLA A*0201-restricted CD8(+) T-cell epitope for the glycoprotein B homolog of human herpesvirus 8. , 2002, Blood.
[8] D. Baarle,et al. Functional restoration of human immunodeficiency virus and Epstein‐Barr virus‐specific CD8+ T cells during highly active antiretroviral therapy is associated with an increase in CD4+ T cells , 2002, European journal of immunology.
[9] B. Gazzard,et al. Identification of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Specific Cytotoxic T-Lymphocyte Epitopes and Evaluation of Reconstitution of KSHV-Specific Responses in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy , 2002, Journal of Virology.
[10] M. Falchi,et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma , 2002, Nature Medicine.
[11] P. Pellett,et al. Highly Sensitive Assay for Human Herpesvirus 8 Antibodies That Uses a Multiple Antigenic Peptide Derived from Open Reading Frame K8.1 , 2002, Journal of Clinical Microbiology.
[12] L. Chieco‐Bianchi,et al. Dynamics of Epstein–Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy , 2002, AIDS.
[13] F. Vannberg,et al. Identification of Human Immunodeficiency Virus Type 1 Subtype C Gag-, Tat-, Rev-, and Nef-Specific Elispot-Based Cytotoxic T-Lymphocyte Responses for AIDS Vaccine Design , 2001 .
[14] D. Baarle,et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. , 2001, Blood.
[15] L. Kingsley,et al. Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. , 2001, Blood.
[16] J. Kaldor,et al. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy , 2001, AIDS.
[17] C. Boshoff,et al. Seroepidemiology and molecular epidemiology of Kaposi's sarcoma-associated herpesvirus among Jewish population groups in Israel. , 2001, Journal of the National Cancer Institute.
[18] E. Rosenberg,et al. Substantial Differences in Specificity of HIV-Specific Cytotoxic T Cells in Acute and Chronic HIV Infection , 2001, The Journal of experimental medicine.
[19] L. Kingsley,et al. CD8+ cytotoxic T lymphocyte responses to lytic proteins of human herpes virus 8 in human immunodeficiency virus type 1-infected and -uninfected individuals. , 2000, The Journal of infectious diseases.
[20] W. Rozenbaum,et al. Quantitative Analysis of Human Herpesvirus 8 Viral Load Using a Real-Time PCR Assay , 2000, Journal of Clinical Microbiology.
[21] S. Kostense,et al. Longitudinal Phenotypic Analysis of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes: Correlation with Disease Progression , 1999, Journal of Virology.
[22] C. Boshoff,et al. Identification of Human Herpesvirus 8-Specific Cytotoxic T-Cell Responses , 1999, Journal of Virology.
[23] A. Muñoz,et al. TIMING OF ANTIBODIES TO HUMAN HERPESVIRUS-8 (HHV-8) AMONG HIV-1 SEROCONVERTERS AND PROGRESSION TO KAPOSI'S SARCOMA , 1999 .
[24] R. Gallo. The Enigmas of Kaposi's Sarcoma , 1998, Science.
[25] B. Chandran,et al. Human herpesvirus-8 ORF K8.1 gene encodes immunogenic glycoproteins generated by spliced transcripts. , 1998, Virology.
[26] D. Scadden. AIDS-related malignancies. , 1998, Current opinion in oncology.
[27] V. Beral,et al. Overview of the epidemiology of immunodeficiency-associated cancers. , 1998, Journal of the National Cancer Institute. Monographs.
[28] C. Pellet,et al. Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. , 1997, AIDS.
[29] A. McMichael,et al. Rapid Effector Function in CD8+ Memory T Cells , 1997, The Journal of experimental medicine.
[30] C. Boshoff,et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma , 1995, The Lancet.
[31] J. Bodmer,et al. Defining the common subtypes of HLA A9, A10, A28 and A19 by use of ARMS/PCR. , 1993, Tissue antigens.
[32] S. Salahuddin,et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients , 1990, Nature.
[33] S. Zeger,et al. Longitudinal data analysis using generalized linear models , 1986 .
[34] I. Flinn,et al. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. , 2000, Blood.